Holen Sie sich die Stockscreener-App
0.726
18.09%
0.1112
Handel nachbörslich:
.70
-0.026
-3.58%
Schlusskurs vom Vortag:
$0.6148
Offen:
$0.649
24-Stunden-Volumen:
267.22K
Relative Volume:
0.24
Marktkapitalisierung:
$1.54M
Einnahmen:
$4.70M
Nettoeinkommen (Verlust:
$-4.99M
KGV:
-0.1131
EPS:
-6.42
Netto-Cashflow:
$-5.29M
1W Leistung:
+7.08%
1M Leistung:
-36.87%
6M Leistung:
-70.73%
1J Leistung:
-60.33%
1-Tages-Spanne:
$0.62
$0.75
1-Wochen-Bereich:
$0.598
$0.75
52-Wochen-Spanne:
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Firmenname
Salarius Pharmaceuticals Inc
Sektor
Branche
Telefon
346-772-0346
Adresse
2450 HOLCOMBE BLVD, HOUSTON
Vergleichen Sie SLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.726 | 1.44M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Aktie (SLRX) Neueste Nachrichten
What analysts say about Salarius Pharmaceuticals Inc. stockExceptional market performance - Autocar Professional
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com
Salarius Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough stock performance - PrintWeekIndia
What drives Salarius Pharmaceuticals Inc. stock priceTurbocharged investment results - Autocar Professional
Is Salarius Pharmaceuticals Inc. a good long term investmentAccelerated financial growth - jammulinksnews.com
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% – What’s Next? - Defense World
How Salarius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Market Return Analysis - Newser
Why Salarius Pharmaceuticals Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
What makes Salarius Pharmaceuticals Inc. stock price move sharplyShort Squeeze Radar - Newser
Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance - MSN
Salarius Pharmaceuticals Granted Extension to Regain Compliance With Nasdaq's Stockholders' Equity Requirement - MarketScreener
Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics - Quiver Quantitative
SLRX gets Nasdaq extension; equity deadline moves to late-July 2025 | NDSN SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Granted Additional Extension to - GlobeNewswire
Salarius Secures Critical Nasdaq Extension Amid $2.5M Equity Requirement Challenge - Stock Titan
Salarius Pharmaceuticals’ Seclidemstat Demonstrates - GlobeNewswire
Salarius Pharmaceuticals, Inc. Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - MarketScreener
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies - GlobeNewswire
Breakthrough Studies Support Salarius Cancer Drug Effectiveness While Clinical Trials Show Promise - Stock Titan
Salarius Pharmaceuticals Approves Reverse Stock Split - The Globe and Mail
Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com Nigeria
Why Is Salarius Pharmaceuticals Stock (SLRX) Up 110% Today? - The Globe and Mail
Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga
What's Going On With Salarius Pharmaceuticals Shares Today? - Benzinga
Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards - Nasdaq
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks
Salarius Pharmaceuticals adjusts merger terms amid market shifts By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals adjusts merger terms amid market shifts - Investing.com Australia
Salarius Pharmaceuticals Enters Second Amendment To Merger Agreement With DecoySEC Filing - MarketScreener
Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Salarius: Q1 Earnings Snapshot - New Haven Register
Finanzdaten der Salarius Pharmaceuticals Inc-Aktie (SLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):